

Form PTO-1449 (modified)

Atty. Docket No.
CLFR:114USSerial No.
08/844,731

List of Patents and Publications for Applicant's Office

Applicant
Staley A. Brod

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
April 21, 1997Group:
1761U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1						

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JS/	C1	Brod, "Ingested IFN-alpha: Results of a pilot study in relapsing-remitting MS," <i>Neurology</i> , 57:845-852, 2001.
/JS/	C2	Cummins <i>et al.</i> , "Oral use of human alpha interferon in cats," <i>J. Biol. Response Mod.</i> 7:513-423. 1988. (abstract)
/JS/	C3	Koren and Fleischmann, "Orally administered interferons suppress bone marrow function," <i>P.S.E.B.M.</i> , 204:155-164, 1993.
/JS/	C4	Soos <i>et al.</i> , "Cutting Edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate," <i>J. Immunol.</i> , 169: 2231-2235, 2002.

25646123.1

EXAMINER: /Jegatheesan Seharaseyon/

DATE CONSIDERED: 05/24/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)